Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In this study, using the Hain GenoType MTBDRsl assays (versions 1 and 2), we found that some nonsynonymous and synonymous mutations in gyrA in Mycobacterium tuberculosis result in systematic false-resistance results to fluoroquinolones by preventing the binding of wild-type probes. Moreover, such mutations can prevent the binding of mutant probes designed for the identification of specific resistance mutations. Although these mutations are likely rare globally, they occur in approximately 7% of multidrug-resistant tuberculosis strains in some settings.

Original publication




Journal article


Antimicrobial agents and chemotherapy

Publication Date





Public Health England West Midlands Public Health Laboratory, Heartlands Hospital, Birmingham, United Kingdom.


Humans, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Fluoroquinolones, DNA Gyrase, Oligonucleotide Probes, Antitubercular Agents, False Positive Reactions, Biological Assay, Phylogeny, Drug Resistance, Multiple, Bacterial, Gene Expression, Mutation